Results 151 to 160 of about 30,661 (234)
Transplantation outcomes in patients with Down syndrome‐associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies
British Journal of Haematology, EarlyView.This nationwide study of 56 patients with Down syndrome‐associated acute lymphoblastic leukaemia (ALL) demonstrated that haematopoietic stem cell transplantation (HSCT) in complete remission (CR)1/2 yields comparable event‐free survival to non‐Down syndrome ALL.Hisashi Ishida, Yasuhiro Okamoto, Hirotoshi Sakaguchi, Yasuyuki Arai, Tomoaki Ueda, Shunsuke Yamamoto, Mio Yano, Tomoko Yokosuka, Keiko Okada, Maho Sato, Shuhei Karakawa, Ryoji Kobayashi, Keisuke Kato, Katsuyoshi Koh, Toshihiro Fujiki, Kumiko Goi, Shoji Saito, Junko Takita, Takako Miyamura, Yuhki Koga, Nao Yoshida, Atsushi Sato, Moeko Hino, Ken Tabuchi, Yuki Arakawa +24 morewiley +1 more sourceDysregulated TIE‐2 expression is associated with blood‐brain barrier leakiness and Alzheimer's disease‐related neuropathology
Brain Pathology, EarlyView.Ince et al., have analysed TIE‐1 and ‐2 expression in human brain tissue, including microvessel‐enriched fractions (MVF) and covering a spectrum of AD‐associated pathology, and in CSF from independent cohorts spanning a clinical spectrum from normal cognition to AD.Selvi Ince, Carol Van Hulle, Gwendlyn Kollmorgen, Clara Quijano‐Rubio, Carey Gleason, Barbara B. Bendlin, Ozioma Okonkwo, Sanjay Asthana, Kaj Blennow, Henrik Zetterberg, Sterling C. Johnson, Seth Love, J. Scott Miners +12 morewiley +1 more sourceNTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2
Cancer Science, EarlyView.Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori +21 morewiley +1 more sourceRUNX1‐Driven CPXM1 Transcription Promotes Malignant Phenotypes and EMT in Gastric Cancer Cells
Cancer Science, EarlyView.RUNX1 transcriptionally activates CPXM1, promotes EMT, and enhances the proliferation, invasion, and metastasis of gastric cancer cells. ABSTRACT
Gastric cancer (GC) remains a leading cause of cancer‐related mortality worldwide, with current treatment strategies largely limited to surgery, chemotherapy, and targeted therapy.Ping Jia, Fengming Xu, Tao Zhou, Pingping Wang, Huiping Chen, Jing Zhang, Xiaochen Yuan, Haoxun Xu, Yu Ouyang +8 morewiley +1 more sourceAdherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 226-238, March 2025.In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.Bernardo Sousa‐Pinto, Elísio M. Costa, Rafael José Vieira, Ludger Klimek, Wienczyslawa Czarlewski, Oliver Pfaar, Anna Bedbrook, Rita Amaral, Luisa Brussino, Violeta Kvedariene, Desiree E. Larenas‐Linnemann, Tomohisa Iinuma, Nhân Pham‐Thi, Frederico S. Regateiro, Luis Taborda‐Barata, Maria Teresa Ventura, Ignacio J. Ansotegui, Karl C. Bergmann, G. Walter Canonica, Victoria Cardona, Lorenzo Cecchi, Ivan Cherrez‐Ojeda, Cemal Cingi, Alvaro A. Cruz, Stefano Del Giacco, Philippe Devillier, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Piotr Kuna, Helga Kraxner, Daniel Laune, Renaud Louis, Michael Makris, Mario Morais‐Almeida, Ralph Mösges, Marek Niedoszytko, Nikolaos G. Papadopoulos, Vincenzo Patella, Ana Margarida Pereira, Sietze Reitsma, Karla Robles‐Velasco, Philip W. Rouadi, Boleslaw Samolinski, Milan Sova, Sanna K. Toppila‐Salmi, Joaquin Sastre, Arunas Valiulis, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, Joao A. Fonseca, Jean Bousquet, the MASK‐air think tank, Josep M. Anto, Maciej Kupczyk, Marek Kulus, Nicolas Roche, Nicola Scichilone, Rute Almeida, Sinthia Bosnic‐Anticevich, Fulvio Braido, Claudia Chaves Loureiro, Govert de Vries, Antonio F. M. Giuliano, Cristina Jácome, Igor Kaidashev, Gilles Louis, Olga Lourenço, Mika Makela, Marcus Maurer, Joaquim Mullol, Rachel Nadif, Robyn O’Hehir, Yoshitaka Okamoto, Markus Ollert, Heidi Olze, Benoit Pétré, Francesca Puggioni, Jan Romantowski, Daniela Rivero‐Yeverino, Monica Rodriguez‐Gonzalez, Ana Sá‐Sousa, Marine Savouré, Faradiba S. Serpa, Mohamed H. Shamji, Aziz Sheikh, Charlotte Suppli Ulrik, Mikhail Sofiev, Annette Sperl, Ana Todo‐Bom, Ioanna Tsiligianni, Erkka Valovirta, Michiel van Eerd, Hubert Blain, Louis‐Philippe Boulet, Guy Brusselle, Roland Buhl, Denis Charpin, Thomas Casale, Tomas Chivato, Jaime Correia‐de‐Sousa, Christopher Corrigan, Frédéric de Blay, Mark Dykewicz, Alessandro Fiocchi, Mattia Giovannini, Ewa Jassem, Marek Jutel, Thomas Keil, Stefania La Grutta, Brian Lipworth, Alberto Papi, Jean‐Louis Pépin, Santiago Quirce, Carlos Robalo Cordeiro, Maria J. Torres, Omar S. Usmani, Matteo Bonini, Brigita Gradauskiene, Christopher Brightling +121 morewiley +1 more sourceCRB1‐Associated Inherited Retinal Dystrophies: Prospective Natural History Study With 4 Years of Follow‐Up
Clinical &Experimental Ophthalmology, EarlyView.ABSTRACT Background
The lack of validated and sensitive clinical endpoints remains a major challenge in the design of gene therapy trials for inherited retinal dystrophies (IRDs). This prospective longitudinal cohort study describes the natural disease progression of IRDs caused by pathogenic mutations in the Crumbs homologue 1 (CRB1) gene, and ...Jessica S. Karuntu, Xuan‐Thanh‐An Nguyen, Mays Talib, Mary J. van Schooneveld, Jan Wijnholds, Maria M. van Genderen, Jos Twisk, Nicoline E. Schalij‐Delfos, Caroline C. W. Klaver, Ralph J. Florijn, Jacoline B. ten Brink, Magda A. Smoor, L. Ingeborgh van den Born, Carel B. Hoyng, Alberta A. H. J. Thiadens, Camiel J. F. Boon +15 morewiley +1 more sourceDefining ecologically realistic biodiversity offset multipliers with the response‐based habitat hectare assessment of biodiversity gains (REHAB)
Conservation Science and Practice, EarlyView.Biodiversity offsetting should be based on adequately large multipliers to deliver no net loss or a net gain for biodiversity, yet the multipliers are often applied without quantitative assessment of the ecological outcomes of offset actions. Here, we show how ecologically realistic offset multipliers were defined based on ecological response estimates Joel Jalkanen, Eini Nieminen, Aapo Ahola, Emma Luoma, Minna Pekkonen, Panu Halme, Janne S. Kotiaho, Heini Kujala +7 morewiley +1 more source